Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of adjuvant AC followed by eribulin in early breast cancer
NCT01328249Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.. Started Mar 2011; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01328249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01328249.